Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018 Clinical development of sparsentan in IgAN and CNSA-001 in PKU expected to initiate in 2018 Revenue
SAN DIEGO , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
SAN DIEGO , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Thursday, February 15, 2018 at 9:00 a.m. ET .
Preliminary full-year 2017 revenue of approximately $155 million SAN DIEGO , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2017 to be
Retrophin obtains exclusive option to purchase Censa post proof-of-concept study Phase 2 proof-of-concept study in PKU patients expected to commence in mid-2018 SAN DIEGO , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced a joint development agreement with Censa
SAN DIEGO , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 9:30 a.m. PT .
SAN DIEGO , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO 2017 Prescriptions for Success Healthcare Conference in New York City on Thursday, December 14, 2017 at 3:00 p.m. ET .
Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million SAN DIEGO, CALIFORNIA -- (Marketwired) -- 11/07/17 -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2017 financial results and provided a corporate
